Office of Economics and Analysis
Beethika Khan, Ph.D., Associate Commissioner for Economics and Analysis
Mission
The Office of Economics and Analysis (OEA) provides public health, economic, and strategic analysis and evaluation to inform FDA’s policy and rulemaking decisions.
Major Functions
OEA advises and assists the Commissioner and senior leadership on the public health, social science, and economic implications of Agency programs, priorities, and initiatives.
We conduct economic, public health, social science, and operations research as a basis for analyzing and forecasting trends, needs, and major problems requiring solutions. We also provide assistance and consultation in these areas to FDA leadership and operating units. We evaluate impacts of external factors on Agency programs, including industry market dynamics, consumer expectations, and prospective legislation. OEA develops regulatory impact analysis for FDA’s rulemaking. OEA also leads the Agency’s engagement in GAO and OIG studies through timely clearance and transmission of requested information.
Office Divisions
OEA is led by the Associate Commissioner for Economics and Analysis, and it consists of two components: The Economics Staff and the Public Health Strategy and Analysis Staff.
The Economics Staff
Ephraim Leibtag, Ph.D., Chief Economist
The Public Health Strategy and Analysis Staff
Lisa Rovin, JD, PHSA Staff Director
Quick Links & Resources
- Regulatory Impact Analyses (RIA)
- Fact Sheet: FDA at a Glance
- Office of Policy, Legislation, and International Affairs
Contact Us
- FDA/OC/OPLIA/Office of Economics and Analysis
- 10903 New Hampshire Ave
Silver Spring, MD 20993 -
Hours Available